Vertex Pharmaceuticals (VRTX) Competitors $397.27 +0.63 (+0.16%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VRTX vs. AMGN, GILD, REGN, ALNY, BIIB, UTHR, NBIX, INCY, BMRN, and EXASShould you be buying Vertex Pharmaceuticals stock or one of its competitors? The main competitors of Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry. Vertex Pharmaceuticals vs. Amgen Gilead Sciences Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, community ranking, valuation, earnings, institutional ownership and dividends. Is VRTX or AMGN more profitable? Amgen has a net margin of 13.00% compared to Vertex Pharmaceuticals' net margin of -4.52%. Amgen's return on equity of 168.35% beat Vertex Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vertex Pharmaceuticals-4.52% -1.91% -1.43% Amgen 13.00%168.35%11.18% Which has more volatility and risk, VRTX or AMGN? Vertex Pharmaceuticals has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Which has better valuation & earnings, VRTX or AMGN? Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVertex Pharmaceuticals$10.63B9.63$3.62B-$1.99-199.63Amgen$32.53B4.35$6.72B$7.8133.72 Does the MarketBeat Community believe in VRTX or AMGN? Vertex Pharmaceuticals received 43 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 75.34% of users gave Vertex Pharmaceuticals an outperform vote while only 72.11% of users gave Amgen an outperform vote. CompanyUnderperformOutperformVertex PharmaceuticalsOutperform Votes158975.34% Underperform Votes52024.66% AmgenOutperform Votes154672.11% Underperform Votes59827.89% Do analysts rate VRTX or AMGN? Vertex Pharmaceuticals presently has a consensus price target of $499.77, indicating a potential upside of 25.80%. Amgen has a consensus price target of $319.67, indicating a potential upside of 21.37%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than Amgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vertex Pharmaceuticals 3 Sell rating(s) 10 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.52Amgen 2 Sell rating(s) 12 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.40 Do institutionals and insiders believe in VRTX or AMGN? 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Amgen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to VRTX or AMGN? In the previous week, Vertex Pharmaceuticals had 27 more articles in the media than Amgen. MarketBeat recorded 43 mentions for Vertex Pharmaceuticals and 16 mentions for Amgen. Amgen's average media sentiment score of 0.56 beat Vertex Pharmaceuticals' score of 0.33 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 11 Very Positive mention(s) 8 Positive mention(s) 11 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Amgen 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive SummaryAmgen beats Vertex Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Vertex Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRTX vs. The Competition Export to ExcelMetricVertex PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.31B$6.57B$5.02B$9.08BDividend YieldN/A3.09%4.87%4.20%P/E Ratio-199.6310.55135.0817.16Price / Sales9.63194.011,120.30115.67Price / Cash31.6457.1640.5837.88Price / Book5.825.104.754.78Net Income$3.62B$151.51M$118.50M$225.60M7 Day Performance-14.33%-2.13%-1.85%-1.21%1 Month Performance-11.58%-3.13%11.28%3.09%1 Year Performance-0.84%11.54%29.91%16.48% Vertex Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRTXVertex Pharmaceuticals4.7499 of 5 stars$397.27+0.2%$499.77+25.8%-0.7%$102.31B$10.63B-199.635,400Analyst ForecastNews CoverageHigh Trading VolumeAMGNAmgen4.4671 of 5 stars$269.39-0.5%$319.68+18.7%-4.3%$144.81B$32.53B34.8626,700Analyst DowngradeGap UpGILDGilead Sciences4.4865 of 5 stars$92.73+0.9%$96.43+4.0%+17.8%$115.57B$27.12B1,020.6718,000Insider TradeREGNRegeneron Pharmaceuticals4.645 of 5 stars$733.02+0.2%$1,099.90+50.1%-16.6%$80.55B$13.12B18.1013,450Analyst ForecastALNYAlnylam Pharmaceuticals4.4024 of 5 stars$246.53+0.4%$298.09+20.9%+37.1%$31.80B$1.83B-93.682,100Analyst UpgradeBIIBBiogen4.6223 of 5 stars$151.25+0.8%$245.32+62.2%-41.0%$22.04B$9.61B13.697,570Analyst DowngradeUTHRUnited Therapeutics4.708 of 5 stars$370.95+2.5%$370.860.0%+59.5%$16.56B$2.76B16.221,168Analyst DowngradeInsider TradePositive NewsNBIXNeurocrine Biosciences4.8222 of 5 stars$134.00+5.8%$165.00+23.1%+12.6%$13.57B$2.24B35.791,400Analyst ForecastInsider TradePositive NewsINCYIncyte4.6959 of 5 stars$70.38+2.7%$76.13+8.2%+13.3%$13.56B$4.08B489.642,524Analyst ForecastBMRNBioMarin Pharmaceutical4.9824 of 5 stars$66.07+0.1%$94.20+42.6%-29.1%$12.59B$2.75B39.533,401Positive NewsEXASExact Sciences4.4854 of 5 stars$60.48-1.3%$72.94+20.6%-11.7%$11.19B$2.50B-52.356,600 Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vertex Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Vertex Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRTX Stock Alerts